The Role of Metabolomics and Biomarker Analysis in Early Phase Clinical Trials
The rise of metabolomics and biomarker analysis in early phase clinical trials is reshaping how development teams evaluate pharmacological activity, human variability, and early indicators of safety. For regulatory professionals, these tools present both opportunity and complexity. They offer stronger evidentiary support for early mechanistic understanding, yet they also introduce new demands around data interpretation, […]